ArticleThe oncologist2021

First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

Khanh T Do et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.